Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An abnormal increase in CD26(-)CD28(-) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus.
Hatano R, Nakamura H, Yamamoto A, Otsuka H, Itoh T, Hosokawa N, Yu J, Ranjbar S, Hasegawa Y, Sato T, Dang NH, Ohnuma K, Morimoto S, Sekigawa I, Ishii T, Morimoto C. Hatano R, et al. Among authors: hosokawa n. Int Immunol. 2024 Oct 9:dxae062. doi: 10.1093/intimm/dxae062. Online ahead of print. Int Immunol. 2024. PMID: 39383111
Visualization of ER-to-Golgi trafficking of procollagen X.
Ximin Y, Hashimoto H, Wada I, Hosokawa N. Ximin Y, et al. Among authors: hosokawa n. Cell Struct Funct. 2024 Oct 2;49(2):67-81. doi: 10.1247/csf.24024. Epub 2024 Sep 6. Cell Struct Funct. 2024. PMID: 39245571 Free article.
Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers.
Fujita H, Arai S, Arakawa H, Hamamoto K, Kato T, Arai T, Nitta N, Hotta K, Hosokawa N, Ohbayashi T, Takahashi C, Inokuma Y, Tamai I, Yano S, Kunishima M, Watanabe Y. Fujita H, et al. Among authors: hosokawa n. Bioorg Med Chem. 2024 Mar 15;102:117674. doi: 10.1016/j.bmc.2024.117674. Epub 2024 Mar 2. Bioorg Med Chem. 2024. PMID: 38457912
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K. Maeda H, et al. Among authors: hosokawa n. Expert Rev Vaccines. 2024 Jan-Dec;23(1):213-225. doi: 10.1080/14760584.2024.2310807. Epub 2024 Feb 8. Expert Rev Vaccines. 2024. PMID: 38288980 Free article.
231 results